@Bigrock2402
There are 2 other players targeting inflammation in the DMD space. Interestingly they are both listed.
Catabasis - CATB.NAS - mkt cap US$126m (1 drug only targeting DMD)
https://www.catabasis.com/CATB-MoveDMD-48-60-Week-Results_13Feb2018_FINAL.pdf
Capicor - CAPR (OTC) - mkt cap US$68m (1 drug only targeting DMD) recent P2 results showed minimal efficacy compared to ANP)
https://www.catabasis.com/CATB-MoveDMD-48-60-Week-Results_13Feb2018_FINAL.pdf
Now... just waiting for the shakedown from Akki.. every post i have put up has had a response from Akki with a very strong negative tone, because Akki knows more than anyone here, is a better investor and more informed than all of us. Don’t let me down Akki.
Companies competing with ANP in DMD space
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 13.5¢ | $23.78K | 176.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 551990 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 193055 | 3 |
View Market Depth
| Last trade - 10.10am 14/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |